Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HPD | P32754 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137355 | 0.90 | PTGS2 (0.49) | PTGS2KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL17936437 | 0.85 | ALDH1A1 (0.45) | KMT2ASMN1; SMN2ALDH1A1MAPTHTT | |
| SCHEMBL26110946 | 0.84 | KMT2A (0.47) | PTGS2KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL30596982 | 0.84 | KMT2A (0.47) | PTGS2KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL25293041 | 0.80 | MAPT (0.44) | KMT2ASMN1; SMN2KCNN4ALDH1A1MAPT | |
| SCHEMBL27693986 | 0.79 | L3MBTL1 (0.47) | KMT2ASMN1; SMN2ALDH1A1MAPTLMNA | |
| SCHEMBL5107176 | 0.79 | HPGD (0.56) | KMT2ASMN1; SMN2KCNN4ALDH1A1MAPT | |
| SCHEMBL30297160 | 0.78 | TDP1 (0.53) | KMT2ASMN1; SMN2ALDH1A1MAPTHTT | |
| SCHEMBL6117 | 0.78 | TDP1 (0.53) | KMT2ASMN1; SMN2ALDH1A1MAPTHTT | |
| SCHEMBL2060423 | 0.78 | NPC1 (0.46) | KMT2ASMN1; SMN2KCNN4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | NR3C2, MC2R, NR3C1 | PTGS2 737/4885KMT2A 2289/4885SMN1; SMN2 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.